News Releases News Releases Year None202120202019201820172016 Mar 01, 2021 Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr Feb 09, 2021 Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer Feb 08, 2021 Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic Jan 31, 2021 Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells Jan 26, 2021 Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients Jan 19, 2021 Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein Jan 19, 2021 Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021 Jan 10, 2021 Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
News Releases Year None202120202019201820172016 Mar 01, 2021 Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr Feb 09, 2021 Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer Feb 08, 2021 Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic Jan 31, 2021 Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells Jan 26, 2021 Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients Jan 19, 2021 Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein Jan 19, 2021 Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021 Jan 10, 2021 Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4
Mar 01, 2021 Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
Feb 09, 2021 Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Feb 08, 2021 Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
Jan 31, 2021 Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
Jan 26, 2021 Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Jan 19, 2021 Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
Jan 19, 2021 Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021
Jan 10, 2021 Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference
